loading...| Preferred Name |
atezolizumab |
|
| Synonyms |
MPDL-3280A |
|
| ID |
http://purl.bioontology.org/ontology/MESH/C000594389 |
|
| altLabel |
MPDL-3280A immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MDPL3280a heavy chain), disulfide with human monoclonal MDPL3280a kappa-chain, dimer RG7446 RG-7446 Tecentriq anti-PDL1 MPDL3280A |
|
| cui |
C4055433 C3827082 C3853941 C4238884 |
|
| HM |
D061067 |
|
| II |
D060890 |
|
| Inverse of RB |
52CMI0WC3Y |
|
| isa | ||
| LT |
TRD |
|
| Mapped to | ||
| MDA |
20150111 |
|
| MeSH Frequency |
1052 |
|
| MMR |
20220131 |
|
| notation |
C000594389 |
|
| PA |
D000970 D000082082 |
|
| prefLabel |
atezolizumab |
|
| SC |
1 |
|
| Scope Statement |
A monoclonal antibody that targets programmed death-ligand 1 (CD274 ANTIGEN) and is used to treat urothelial carcinoma, the most common type of bladder cancer. |
|
| SRC |
Cancer Control. 2014 Jan;21(1):80-9. |
|
| TERMUI |
T000873456 T000908861 T000908611 T000965499 T000908860 T000902412 T000908610 T000908609 |
|
| TH |
NLM (2016) NLM (2020) FDA SRS (2017) NLM (2015) USAN (19XX) INN (19XX) NLM (2017) |
|
| tui |
T109 T116 T129 T121 |